Mucosolvan Hustensaft (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Mucosolvan Hustensaft, is a mucolytic presented as a syrup for oral use. It facilitates the clearance of thick bronchial secretions, helping to relieve productive cough associated with bronchitis, upper respiratory tract infections and other respiratory disorders in both adults and children.

GNH USA supplies Mucosolvan Hustensaft as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU GMP standards and providing the product to hospitals, pharmacies and clinics worldwide through a validated supply chain and reliable.

Ambroxol Hydrochloride is a mucolytic that acts on respiratory secretions to improve clearance in several common conditions. - Productive cough: Reduces mucus viscosity, facilitating expectoration and easing the cough associated with excess bronchial secretions. - Acute bronchitis: Enhances mucociliary clearance, helping to relieve cough and improve breathing during the inflammatory phase of bronchial infection. - Upper respiratory tract infections: Assists in clearing thick secretions, supporting symptom relief and faster recovery in infections of the nasal passages, throat and bronchi.

Ambroxol Hydrochloride is generally well tolerated, but some patients may experience adverse reactions. Common Side Effects: - Taste disturbance: transient bitter or metallic taste in the mouth. - Nausea: mild stomach upset or feeling of queasiness. - Diarrhea: loose stools occurring shortly after ingestion. - Skin rash: mild erythema or itching at the site of contact. Serious or Rare Side Effects: - Allergic reaction: hives, swelling, or difficulty breathing indicating possible anaphylaxis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or jaundice in rare cases. - Bronchospasm: paradoxical tightening of airways, especially in patients with asthma.

When using Ambroxol Hydrochloride syrup, certain precautions should be observed to ensure safety and effectiveness. - Age limitation: Use with caution in children under two years; dosage must be determined by a healthcare professional. - Pregnancy and lactation: Consult a physician before use, as safety data are limited. - Existing respiratory disease: Monitor patients with asthma or chronic obstructive pulmonary disease for bronchospasm. - Drug hypersensitivity: Avoid if the patient has known allergy to ambroxol or similar mucolytics. - Concomitant medications: Review all current medicines with a clinician to prevent potential interactions. - Store at ambient temperature: Keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Ambroxol Hydrochloride may interact with other medicines; awareness of significant interactions helps to avoid reduced efficacy or increased toxicity. Major Interactions (Avoid): - Anticholinergic agents: May diminish the secretomotor stimulation effect of ambroxol. - Strong CYP3A4 inhibitors: Potentially increase systemic exposure, though clinical relevance is low. Moderate Interactions (Monitor Closely): - Bronchodilators: Combined use may enhance cough reflex, requiring observation. - Antibiotics for respiratory infections: No direct interaction, but concurrent therapy should be coordinated. - Antihistamines: May mask mucosal irritation, necessitating monitoring of symptom relief.